172 related articles for article (PubMed ID: 8892461)
21. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
22. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
23. Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.
Rave-Fränk M; Glomme S; Hertig J; Weiss E; Pradier O; Hess CF; Virsik-Köpp P; Schmidberger H
Strahlenther Onkol; 2002 Sep; 178(9):497-503. PubMed ID: 12426836
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
Zhang Y; Chen X; Ren P; Su Z; Cao H; Zhou J; Zou X; Fu S; Lin S; Fan J; Yang B; Sun X; Zhou Y; Chen Y; Yang L; Wu J
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):356-62. PubMed ID: 23906928
[TBL] [Abstract][Full Text] [Related]
25. Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
Chastagner P; Kozin SV; Taghian A
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):777-82. PubMed ID: 11395247
[TBL] [Abstract][Full Text] [Related]
26. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
27. [Topoisomerase I inhibitor with potential radiosensitizing effect].
Sauer R; Heuser A
Strahlenther Onkol; 1997 Mar; 173(3):125-30. PubMed ID: 9122851
[TBL] [Abstract][Full Text] [Related]
28. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Kaufmann SH; Svingen PA; Gore SD; Armstrong DK; Cheng YC; Rowinsky EK
Blood; 1997 Mar; 89(6):2098-104. PubMed ID: 9058732
[TBL] [Abstract][Full Text] [Related]
29. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
30. Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Ohneseit PA; Wildemann A; Herskind C; Bamberg M; Rodemann HP
Int J Radiat Biol; 2002 Feb; 78(2):125-32. PubMed ID: 11779362
[TBL] [Abstract][Full Text] [Related]
31. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
33. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
[TBL] [Abstract][Full Text] [Related]
34. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
35. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher BA; Holden SA; Khandakar V; Herman TS
J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
[TBL] [Abstract][Full Text] [Related]
36. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
37. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
38. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Zhang JL; Sharma PL; Li CJ; Dezube BJ; Pardee AB; Crumpacker CS
Antimicrob Agents Chemother; 1997 May; 41(5):977-81. PubMed ID: 9145855
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Taron M; Plasencia C; Abad A; Martin C; Guillot M
Invest New Drugs; 2000 May; 18(2):139-47. PubMed ID: 10857993
[TBL] [Abstract][Full Text] [Related]
40. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
